AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JAN 1 - (NewsRx.com & NewsRx.net) -- U.S. National Institutes of Health researchers investigated the effect of intranasal immunization with a detoxified-lipooligosaccharide-cross-reactive mutant of diphtheria toxin (dLOS-CRM) vaccine candidate on pulmonary clearance following an aerosol challenge of mice with Moraxella catarrhalis."
"Moraxella catarrhalis is an important human mucosal pathogen," noted X.N. Jiao and colleagues.
"Intranasal immunization with dLOS-CRM plus cholera toxin induced a significantly dose-dependent increase of immunoglobulin A (IgA) and IgG in the nasal wash, lung lavage fluid, saliva, and fecal extract [of the mice]," the researchers reported.
"In addition, serum IgG, IgM, and IgA against LOS of M. catarrhalis were detected. LOS-specific antibody-forming cells were found in the nasal passages, spleens, nasally associated lymphoid tissues, cervical lymph nodes, lungs, and Peyer's patches using an enzyme-linked immunospot assay.
"The dLOS-CRM vaccine induced a significant bacterial clearance (70% to 90%) of both homologous and heterologous strains in the lungs compared to that observed in the controls (p
"Intriguingly," they said, "intranasal immunization with dLOS-CRM showed a higher level of bacterial clearance compared with subcutaneous injections with dLOS-CRM."
"These data ...
Source: HighBeam Research, Intranasal dLOS-CRM vaccine against Moraxella catarrhalis studied.